ReviewInternational journal of molecular sciences2012
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?
Review in International journal of molecular sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 39 citations in OpenAlex.
- The therapeutic potential of exercise for improving mobility in multiple sclerosis.Frontiers in physiology · 2024Review
- Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis.Multiple sclerosis and related disorders · 2022Article
- Inflammatory cytokines derived from peripheral blood contribute to the modified electroconvulsive therapy-induced cognitive deficits in major depressive disorder.European archives of psychiatry and clinical neuroscience · 2021Article
- The effects of transplanted mesenchymal stem cells treated with 17-b estradiol on experimental autoimmune encephalomyelitis.Molecular biology reports · 2019Article
- Advances in the treatment of relapsing-remitting multiple sclerosis: the role of pegylated interferon β-1a.Degenerative neurological and neuromuscular disease · 2017Review
- Probabilistic Modeling of Imaging, Genetics and Diagnosis.IEEE transactions on medical imaging · 2016Article
- Distinguishing Susac's syndrome from multiple sclerosis.Journal of neurology · 2015Review
- Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.CNS drugs · 2014Review
- Multiple sclerosis: from molecules to treatment.International journal of molecular sciences · 2013Article
- Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.Mediators of inflammation · 2013Review
- Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis is a potentially debilitating disease of the central nervous system. A concerted program of research by many centers around the world has consistently demonstrated the importance of the immune system in its pathogenesis. This knowledge has led to the formal testing of a number of therapeutic agents in both animal models and humans. These clinical trials have shed yet further light on the pathogenesis of MS through their sometimes unexpected effects and by their differential effects in terms of impact on relapses, progression of the disease, paraclinical parameters (MRI) and the adverse events that are experienced. Here we review the currently approved medications for the commonest form of multiple sclerosis (relapsing-remitting) and the emerging therapies for which preliminary results from phase II/III clinical trials are available. A detailed analysis of the molecular mechanisms responsible for the efficacy of these medications in multiple sclerosis indicates that blockade or modulation of both T- and B-cell activation and migration pathways in the periphery or CNS can lead to amelioration of the disease. It is hoped that further therapeutic trials will better delineate the pathogenesis of MS, ultimately leading to even better treatments with fewer adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.